BeOne Medicines anuncia la publicación de los datos de fase 3 HERIZON-GEA en NEJM y su presentación en ASCO 2026

Key Takeaway: BeOne Medicines has announced the publication of phase 3 HERIZON-GEA data in NEJM and its upcoming presentation at ASCO 2026. This marks a significant milestone for the company as it shares important findings from its clinical trials. The details of the data and its implications for future treatments are yet to be fully disclosed.